Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | PPARA | Q07869 | 5/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917265 | 0.89 | PPARG (0.46) | PPARGPPARAPTGES | |
| SCHEMBL4923368 | 0.85 | PPARG (0.45) | PPARGPPARAPTGESSMN1; SMN2THRB | |
| SCHEMBL3007687 | 0.85 | PPARG (0.45) | PPARGPPARAPTGESSMN1; SMN2THRB | |
| SCHEMBL4702525 | 0.85 | PTGES (0.40) | PTGESSMN1; SMN2THRBPOLBMAPT | |
| SCHEMBL4916762 | 0.82 | ALDH1A1 (0.43) | PPARGPPARAPOLBMAPTTP53 | |
| SCHEMBL4916920 | 0.81 | ELANE (0.41) | PPARGPPARASMN1; SMN2THRBPOLB | |
| SCHEMBL4216575 | 0.78 | PPARG (0.44) | PPARGPPARAPTGES | |
| SCHEMBL333812 | 0.78 | ALOX5 (0.43) | PPARGPPARASMN1; SMN2THRBPOLB | |
| SCHEMBL335343 | 0.78 | THRB (0.44) | PPARGPPARASMN1; SMN2THRBAKR1C3 | |
| SCHEMBL333737 | 0.78 | PPARG (0.45) | PPARGPPARAPTGESSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | PPARG 2586/4885PPARA 3339/4885PTGES 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.